Steven M Dubinett

Dean, Deans Office-School Of Medicin, University of California Los Angeles

Professor, Medicine, University of California Los Angeles

Professor, Pathology and Laboratory Medicine, University of California Los Angeles

Professor, Molecular and Medical Pharmacology, University of California Los Angeles

(310) 267-2725

UC Profile
https://ucla.researcherprofiles.org/steven.dubinett
UCLA Division of Pulmonary, Critical Care, and Sleep Medicine
UCLA Jonsson Comprehensive Cancer Center
UCLA Clinical and Translational Science Institute

Steven M. Dubinett is director of the UCLA Clinical & Translational Science Institute, Associate Vice Chancellor and Senior Associate Dean for Translational Research. He oversees the translation of UCLA biomedical discoveries into medical products and health interventions and is responsible for the efficient integration of the research infrastructure through the CTSI. He is former Chair of the Executive Committee of UC Biomedical Research Acceleration, Integration, and Development (UC BRAID), which integrates clinical and translational research across the University of California. Dr. Dubinett has extensive experience in translational investigation, academic administration, mentorship and peer review. He has trained more than 45-graduate students, post-doctoral fellows and junior faculty, nearly all of whom have continued in academic or industry research careers. Building on original discoveries relevant to inflammation and immunity in lung cancer, he developed a translational research program, which utilizes these laboratory-based discoveries in the translational and clinical environment. As a NCI Translational Research Working Group member, he participated in designing pathways to clinical goals. He previously served as Director for Biomarker Development for the American College of Surgeons Oncology Group, directing biospecimen utilization in the context of clinical trials. Dr. Dubinett serves as the Chair of the Research Evaluation Panel for biospecimen utilization for the American College of Radiology Imaging Network/ National Lung Screening Trial. He previously chaired the FDA Cellular, Tissue & Gene Therapies Advisory Committee and serves on the NCI Thoracic Malignancy Steering Committee as a Translational Science.

Interests

pathogenesis of lung cancer, translational research, immunobiology of lung cancer, human non-small cell lung cancer, microenvironment, inflammation and epithelial mesenchymal transition, lung cancer

Education and Training

Harvard Medical SchoolResident Fellow06/1988Tumor Immunology
Massachusetts General HospitalFellow06/1988Pulmonary Medicine
University of California, Los AngelesChief Resident06/1984Internal Medicine
University of California, Los AngelesResidency06/1983Internal Medicine
University HospitalInternship06/1981Internal Medicine
Rutgers New Jersey Medical SchoolM.D.06/1980Medicine

Awards and Honors

  • New Investigator Award, UC Tobacco-Related Disease Research Program, 1990.
  • Career Investigator Award, American Lung Association, 1996.
  • William S. Middleton Award, U.S. Department of Veterans Affairs, 2019.
  • 2019 Lung Force Honoree, American Lung Association, 2019.
  • Continued Support and Dedication to their Mission and the Advancement of the Field of Lung Cancer, Uniting Against Lung Cancer, 2012.
  • Cecile Lehman Mayer Research Award, American College of Chest Physicians, 1987.
  • American Thoracic Society Recognition Award for Scientific Accomplishments, American Thoracic Society, 2008.
  • 46th Annual Harold J. Jeghers Memorial Lecture, 2014.
  • Young Investigator Award, Southern California Pulmonary Research Conference, 1989.
  • UCLA rep. for research presentations/signing ceremonies for translational medicine agreements, Chinese Academy of Sciences in Beijing and Shanghai with Chancellor Gene Block, 2011.
  • Chair, FDA Cellular, Tissue and Gene Therapies Advisory Committee, 2011.
  • The Stanley Blatt Award for Lung Cancer Research, 1999.
  • Dwyer Award, Jonsson Comprehensive Cancer Center, 1994.
  • Helen Neufeld Research Career Development Award (Stop Cancer Award), 1995.
  • Medical Excellence Award, Barlow Respiratory Hospital, 2014.
  • The Philip J. Browning Memorial Lecture, Meharry Medical College/Vanderbilt Ingram Cancer Center, 2009.

Publications

  1. Saggese P, Pandey A, Alcaraz M, Fung E, Hall A, Yanagawa J, Rodriguez EF, Grogan TR, Giurato G, Nassa G, Salvati A, Shirihai OS, Weisz A, Dubinett SM, Scafoglio C. Glucose deprivation promotes pseudo-hypoxia and de-differentiation in lung adenocarcinoma.. Cancer research, 2023.
  2. Abascal J, Oh MS, Liclican EL, Dubinett SM, Salehi-Rad R, Liu B. Dendritic Cell Vaccination in Non-Small Cell Lung Cancer: Remodeling the Tumor Immune Microenvironment.. Cells, 2023.
  3. Yanagawa J, Tran LM, Salehi-Rad R, Lim RJ, Dumitras C, Fung E, Wallace WD, Prosper AE, Fishbein G, Shea C, Hong R, Kahangi B, Deng JJ, Gower AC, Liu B, Campbell JD, Mazzilli SA, Beane JE, Kadara H, Lenburg ME, Spira AE, Aberle DR, Krysan K, Dubinett SM. Single-Cell Characterization of Pulmonary Nodules Implicates Suppression of Immunosurveillance across Early Stages of Lung Adenocarcinoma.. Cancer research, 2023.
  4. Salehi-Rad R, Lim RJ, Du Y, Tran LM, Li R, Ong SL, Ling Huang Z, Dumitras C, Zhang T, Park SJ, Crosson W, Kahangi B, Abascal J, Seet C, Oh M, Shabihkhani M, Paul M, Krysan K, Lisberg AE, Garon EB, Liu B, Dubinett SM. CCL21-DC in situ vaccination in murine NSCLC overcomes resistance to immunotherapy and generates systemic tumor-specific immunity.. Journal for immunotherapy of cancer, 2023.
  5. Li S, Zeng W, Ni X, Liu Q, Li W, Stackpole ML, Zhou Y, Gower A, Krysan K, Ahuja P, Lu DS, Raman SS, Hsu W, Aberle DR, Magyar CE, French SW, Han SB, Garon EB, Agopian VG, Wong WH, Dubinett SM, Zhou XJ. Comprehensive tissue deconvolution of cell-free DNA by deep learning for disease diagnosis and monitoring.. Proceedings of the National Academy of Sciences of the United States of America, 2023.
  6. Liu S, Dharanipragada P, Lomeli SH, Wang Y, Zhang X, Yang Z, Lim RJ, Dumitras C, Scumpia PO, Dubinett SM, Moriceau G, Johnson DB, Moschos SJ, Lo RS. Multi-organ landscape of therapy-resistant melanoma.. Nature medicine, 2023.
  7. Hu J, Tan P, Ishihara M, Bayley NA, Schokrpur S, Reynoso JG, Zhang Y, Lim RJ, Dumitras C, Yang L, Dubinett SM, Jat PS, Van Snick J, Huang J, Chin AI, Prins RM, Graeber TG, Xu H, Wu L. Tumor heterogeneity in VHL drives metastasis in clear cell renal cell carcinoma.. Signal transduction and targeted therapy, 2023.
  8. Kammer MN, Mori H, Rowe DJ, Chen SC, Vasiukov G, Atwater T, Senosain MF, Antic S, Zou Y, Chen H, Peikert T, Deppen S, Grogan EL, Massion PP, Dubinett S, Lenburg M, Borowsky A, Maldonado F. Tumoral Densities of T-Cells and Mast Cells Are Associated With Recurrence in Early-Stage Lung Adenocarcinoma.. JTO clinical and research reports, 2023.
  9. Han M, Bushong EA, Segawa M, Tiard A, Wong A, Brady MR, Momcilovic M, Wolf DM, Zhang R, Petcherski A, Madany M, Xu S, Lee JT, Poyurovsky MV, Olszewski K, Holloway T, Gomez A, John MS, Dubinett SM, Koehler CM, Shirihai OS, Stiles L, Lisberg A, Soatto S, Sadeghi S, Ellisman MH, Shackelford DB. Spatial mapping of mitochondrial networks and bioenergetics in lung cancer.. Nature, 2023.
  10. Saggese P, Pandey A, Fung E, Hall A, Yanagawa J, Rodriguez EF, Grogan TR, Giurato G, Nassa G, Salvati A, Weisz A, Dubinett SM, Scafoglio C. Glucose deprivation promotes pseudo-hypoxia and de-differentiation in lung adenocarcinoma.. bioRxiv : the preprint server for biology, 2023.
  11. Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, Hernandez SD, Dai E, Cao X, Hu J, Dang M, Wang R, Chu Y, Song X, Zhang J, Parra ER, Wargo JA, Swisher SG, Cascone T, Sepesi B, Futreal AP, Li M, Dubinett SM, Fujimoto J, Solis Soto LM, Wistuba II, Stevenson CS, Spira A, Shalapour S, Kadara H, Wang L. The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma.. Cancer discovery, 2022.
  12. Stackpole ML, Zeng W, Li S, Liu CC, Zhou Y, He S, Yeh A, Wang Z, Sun F, Li Q, Yuan Z, Yildirim A, Chen PJ, Winograd P, Tran B, Lee YT, Li PS, Noor Z, Yokomizo M, Ahuja P, Zhu Y, Tseng HR, Tomlinson JS, Garon E, French S, Magyar CE, Dry S, Lajonchere C, Geschwind D, Choi G, Saab S, Alber F, Wong WH, Dubinett SM, Aberle DR, Agopian V, Han SB, Ni X, Li W, Zhou XJ. Cost-effective methylome sequencing of cell-free DNA for accurately detecting and locating cancer.. Nature communications, 2022.
  13. Shin DS, Park K, Garon E, Dubinett S. Targeting EZH2 to overcome the resistance to immunotherapy in lung cancer.. Seminars in oncology, 2022.
  14. Basu A, Paul MK, Alioscha-Perez M, Grosberg A, Sahli H, Dubinett SM, Weiss S. Statistical parametrization of cell cytoskeleton reveals lung cancer cytoskeletal phenotype with partial EMT signature.. Communications biology, 2022.
  15. Li S, Zeng W, Ni X, Zhou Y, Stackpole ML, Noor ZS, Yuan Z, Neal A, Memarzadeh S, Garon EB, Dubinett SM, Li W, Zhou XJ. cfTrack: A Method of Exome-Wide Mutation Analysis of Cell-free DNA to Simultaneously Monitor the Full Spectrum of Cancer Treatment Outcomes Including MRD, Recurrence, and Evolution.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2022.
  16. Govindan R, Aggarwal C, Antonia SJ, Davies M, Dubinett SM, Ferris A, Forde PM, Garon EB, Goldberg SB, Hassan R, Hellmann MD, Hirsch FR, Johnson ML, Malik S, Morgensztern D, Neal JW, Patel JD, Rimm DL, Sagorsky S, Schwartz LH, Sepesi B, Herbst RS. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.. Journal for immunotherapy of cancer, 2022.
  17. Liu S, Knochelmann HM, Lomeli SH, Hong A, Richardson M, Yang Z, Lim RJ, Wang Y, Dumitras C, Krysan K, Timmers C, Romeo MJ, Krieg C, O'Quinn EC, Horton JD, Dubinett SM, Paulos CM, Neskey DM, Lo RS. Response and recurrence correlates in individuals treated with neoadjuvant anti-PD-1 therapy for resectable oral cavity squamous cell carcinoma.. Cell reports. Medicine, 2021.
  18. Shahrouki P, Lee JM, Barclay J, Khan SN, Genshaft S, Abtin F, Dubinett SM, Lisberg A, Sharma S, Garon EB, Suh R. Technical Feasibility and Safety of Repeated Computed Tomography-Guided Transthoracic Intratumoral Injection of Gene-Modified Cellular Immunotherapy in Metastatic NSCLC.. JTO clinical and research reports, 2021.
  19. Carson SL, Casillas A, Castellon-Lopez Y, Mansfield LN, Morris D, Barron J, Ntekume E, Landovitz R, Vassar SD, Norris KC, Dubinett SM, Garrison NA, Brown AF. COVID-19 Vaccine Decision-making Factors in Racial and Ethnic Minority Communities in Los Angeles, California.. JAMA network open, 2021.
  20. Kadara H, Tran LM, Liu B, Vachani A, Li S, Sinjab A, Zhou XJ, Dubinett SM, Krysan K. Early Diagnosis and Screening for Lung Cancer.. Cold Spring Harbor perspectives in medicine, 2021.
  21. Saggese P, Martinez CA, Tran LM, Lim R, Dumitras C, Grogan T, Elashoff D, Ramin SR, Dubinett SM, Liu B, Scafoglio C. Genotoxic Treatment Enhances Immune Response in a Genetic Model of Lung Cancer.. Cancers, 2021.
  22. Li S, Noor ZS, Zeng W, Stackpole ML, Ni X, Zhou Y, Yuan Z, Wong WH, Agopian VG, Dubinett SM, Alber F, Li W, Garon EB, Zhou XJ. Sensitive detection of tumor mutations from blood and its application to immunotherapy prognosis.. Nature communications, 2021.
  23. William WN, Zhao X, Bianchi JJ, Lin HY, Cheng P, Lee JJ, Carter H, Alexandrov LB, Abraham JP, Spetzler DB, Dubinett SM, Cleveland DW, Cavenee W, Davoli T, Lippman SM. Immune evasion in HPV- head and neck precancer-cancer transition is driven by an aneuploid switch involving chromosome 9p loss.. Proceedings of the National Academy of Sciences of the United States of America, 2021.
  24. Sinjab A, Han G, Treekitkarnmongkol W, Hara K, Brennan PM, Dang M, Hao D, Wang R, Dai E, Dejima H, Zhang J, Bogatenkova E, Sanchez-Espiridion B, Chang K, Little DR, Bazzi S, Tran LM, Krysan K, Behrens C, Duose DY, Parra ER, Raso MG, Solis LM, Fukuoka J, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Rosen D, Heymach JV, Scheet P, Dubinett SM, Fujimoto J, Wistuba II, Stevenson CS, Spira A, Wang L, Kadara H. Resolving the Spatial and Cellular Architecture of Lung Adenocarcinoma by Multiregion Single-Cell Sequencing.. Cancer discovery, 2021.
  25. Li R, Salehi-Rad R, Crosson W, Momcilovic M, Lim RJ, Ong SL, Huang ZL, Zhang T, Abascal J, Dumitras C, Jing Z, Park SJ, Krysan K, Shackelford DB, Tran LM, Liu B, Dubinett SM. Inhibition of Granulocytic Myeloid-Derived Suppressor Cells Overcomes Resistance to Immune Checkpoint Inhibition in LKB1-Deficient Non-Small Cell Lung Cancer.. Cancer research, 2021.
  26. Ford DE, Johnson A, Nichols JJ, Rothwell E, Dubinett S, Naeim A. Challenges and lessons learned for institutional review board procedures during the COVID-19 pandemic.. Journal of clinical and translational science, 2021.
  27. Han G, Sinjab A, Hara K, Treekitkarnmongkol W, Brennan P, Chang K, Bogatenkova E, Sanchez-Espiridion B, Behrens C, Solis LM, Gao B, Girard L, Zhang J, Sepesi B, Cascone T, Byers LA, Gibbons DL, Chen J, Moghaddam SJ, Ostrin EJ, Scheet P, Fujimoto J, Shay J, Heymach JV, Minna JD, Dubinett S, Wistuba II, Stevenson CS, Spira AE, Wang L, Kadara H. Single-Cell Expression Landscape of SARS-CoV-2 Receptor ACE2 and Host Proteases in Normal and Malignant Lung Tissues from Pulmonary Adenocarcinoma Patients.. Cancers, 2021.
  28. Young PA, Márquez-Garbán DC, Noor ZS, Moatamed N, Elashoff D, Grogan T, Romero T, Sasano H, Saito R, Rausch R, Hamilton N, Dubinett SM, Garon EB, Pietras RJ. Investigation of Combination Treatment With an Aromatase Inhibitor Exemestane and Carboplatin-Based Therapy for Postmenopausal Women With Advanced NSCLC.. JTO clinical and research reports, 2021.
  29. Salehi-Rad R, Li R, Tran LM, Lim RJ, Abascal J, Momcilovic M, Park SJ, Ong SL, Shabihkhani M, Huang ZL, Paul M, Shackelford DB, Krysan K, Liu B, Dubinett SM. Novel Kras-mutant murine models of non-small cell lung cancer possessing co-occurring oncogenic mutations and increased tumor mutational burden.. Cancer immunology, immunotherapy : CII, 2021.
  30. Hong A, Piva M, Liu S, Hugo W, Lomeli SH, Zoete V, Randolph CE, Yang Z, Wang Y, Lee JJ, Lo SJ, Sun L, Vega-Crespo A, Garcia AJ, Shackelford DB, Dubinett SM, Scumpia PO, Byrum SD, Tackett AJ, Donahue TR, Michielin O, Holmen SL, Ribas A, Moriceau G, Lo RS. Durable Suppression of Acquired MEK Inhibitor Resistance in Cancer by Sequestering MEK from ERK and Promoting Antitumor T-cell Immunity.. Cancer discovery, 2020.
  31. Cummings AL, Gukasyan J, Lu HY, Grogan T, Sunga G, Fares CM, Hornstein N, Zaretsky J, Carroll J, Bachrach B, Akingbemi WO, Li D, Noor Z, Lisberg A, Goldman JW, Elashoff D, Bui AAT, Ribas A, Dubinett SM, Rossetti M, Garon EB. Mutational landscape influences immunotherapy outcomes among patients with non-small-cell lung cancer with human leukocyte antigen supertype B44.. Nature cancer, 2020.
  32. Krysan K, Tran LM, Dubinett SM. Immunosurveillance and Regression in the Context of Squamous Pulmonary Premalignancy.. Cancer discovery, 2020.
  33. Schwab K, Hamidi S, Chung A, Lim RJ, Khanlou N, Hoesterey D, Dumitras C, Adeyiga OB, Phan-Tang M, Wang TS, Saggar R, Goldstein J, Belperio JA, Dubinett SM, Kim JT, Salehi-Rad R. Occult Colonic Perforation in a Patient With Coronavirus Disease 2019 After Interleukin-6 Receptor Antagonist Therapy.. Open forum infectious diseases, 2020.
  34. Dost AFM, Moye AL, Vedaie M, Tran LM, Fung E, Heinze D, Villacorta-Martin C, Huang J, Hekman R, Kwan JH, Blum BC, Louie SM, Rowbotham SP, Sainz de Aja J, Piper ME, Bhetariya PJ, Bronson RT, Emili A, Mostoslavsky G, Fishbein GA, Wallace WD, Krysan K, Dubinett SM, Yanagawa J, Kotton DN, Kim CF. Organoids Model Transcriptional Hallmarks of Oncogenic KRAS Activation in Lung Epithelial Progenitor Cells.. Cell stem cell, 2020.
  35. Lim RJ, Liu B, Krysan K, Dubinett SM. Lung Cancer and Immunity Markers.. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2020.
  36. Buhr RG, Jackson NJ, Kominski GF, Dubinett SM, Mangione CM, Ong MK. Readmission Rates for Chronic Obstructive Pulmonary Disease Under the Hospital Readmissions Reduction Program: an Interrupted Time Series Analysis.. Journal of general internal medicine, 2020.
  37. Li R, Ong SL, Tran LM, Jing Z, Liu B, Park SJ, Huang ZL, Walser TC, Heinrich EL, Lee G, Salehi-Rad R, Crosson WP, Pagano PC, Paul MK, Xu S, Herschman H, Krysan K, Dubinett S. Author Correction: Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer.. Scientific reports, 2020.
  38. Salehi-Rad R, Li R, Paul MK, Dubinett SM, Liu B. The Biology of Lung Cancer: Development of More Effective Methods for Prevention, Diagnosis, and Treatment.. Clinics in chest medicine, 2020.
  39. Lee MH, Yanagawa J, Tran L, Walser TC, Bisht B, Fung E, Park SJ, Zeng G, Krysan K, Wallace WD, Paul MK, Girard L, Gao B, Minna JD, Dubinett SM, Lee JM. FRA1 contributes to MEK-ERK pathway-dependent PD-L1 upregulation by KRAS mutation in premalignant human bronchial epithelial cells.. American journal of translational research, 2020.
  40. Buhr RG, Jackson NJ, Dubinett SM, Kominski GF, Mangione CM, Ong MK. Factors Associated with Differential Readmission Diagnoses Following Acute Exacerbations of Chronic Obstructive Pulmonary Disease.. Journal of hospital medicine, 2020.
  41. Garon EB, Chih-Hsin Yang J, Dubinett SM. The Role of Interleukin 1β in the Pathogenesis of Lung Cancer.. JTO clinical and research reports, 2020.
  42. Li R, Ong SL, Tran LM, Jing Z, Liu B, Park SJ, Huang ZL, Walser TC, Heinrich EL, Lee G, Salehi-Rad R, Crosson WP, Pagano PC, Paul MK, Xu S, Herschman H, Krysan K, Dubinett S. Chronic IL-1β-induced inflammation regulates epithelial-to-mesenchymal transition memory phenotypes via epigenetic modifications in non-small cell lung cancer.. Scientific reports, 2020.
  43. Sharma S, Kadam P, Dubinett S. CCL21 Programs Immune Activity in Tumor Microenvironment.. Advances in experimental medicine and biology, 2020.
  44. Momcilovic M, Jones A, Bailey ST, Waldmann CM, Li R, Lee JT, Abdelhady G, Gomez A, Holloway T, Schmid E, Stout D, Fishbein MC, Stiles L, Dabir DV, Dubinett SM, Christofk H, Shirihai O, Koehler CM, Sadeghi S, Shackelford DB. Publisher Correction: In vivo imaging of mitochondrial membrane potential in non-small-cell lung cancer.. Nature, 2020.
  45. Li R, Dubinett SM. Myeloid-derived suppressor cell-dependent inhibition of B cell responses in non-small cell lung cancer.. Translational lung cancer research, 2019.
  46. Momcilovic M, Jones A, Bailey ST, Waldmann CM, Li R, Lee JT, Abdelhady G, Gomez A, Holloway T, Schmid E, Stout D, Fishbein MC, Stiles L, Dabir DV, Dubinett SM, Christofk H, Shirihai O, Koehler CM, Sadeghi S, Shackelford DB. In vivo imaging of mitochondrial membrane potential in non-small-cell lung cancer.. Nature, 2019.
  47. Buhr RG, Jackson NJ, Kominski GF, Dubinett SM, Ong MK, Mangione CM. Comorbidity and thirty-day hospital readmission odds in chronic obstructive pulmonary disease: a comparison of the Charlson and Elixhauser comorbidity indices.. BMC health services research, 2019.
  48. Kadara H, Sivakumar S, Jakubek Y, San Lucas FA, Lang W, McDowell T, Weber Z, Behrens C, Davies GE, Kalhor N, Moran C, El-Zein R, Mehran R, Swisher SG, Wang J, Zhang J, Fujimoto J, Fowler J, Heymach JV, Dubinett S, Spira AE, Ehli EA, Wistuba II, Scheet P. Driver Mutations in Normal Airway Epithelium Elucidate Spatiotemporal Resolution of Lung Cancer.. American journal of respiratory and critical care medicine, 2019.
  49. Corbett SE, Nitzberg M, Moses E, Kleerup E, Wang T, Perdomo C, Perdomo C, Liu G, Xiao X, Liu H, Elashoff DA, Brooks DR, O'Connor GT, Dubinett SM, Spira A, Lenburg ME. Gene Expression Alterations in the Bronchial Epithelium of e-Cigarette Users.. Chest, 2019.
  50. Krysan K, Tran LM, Grimes BS, Fishbein GA, Seki A, Gardner BK, Walser TC, Salehi-Rad R, Yanagawa J, Lee JM, Sharma S, Aberle DR, Spira AE, Elashoff DA, Wallace WD, Fishbein MC, Dubinett SM. The Immune Contexture Associates with the Genomic Landscape in Lung Adenomatous Premalignancy.. Cancer research, 2019.
  51. Hu-Lieskovan S, Lisberg A, Zaretsky JM, Grogan TR, Rizvi H, Wells DK, Carroll J, Cummings A, Madrigal J, Jones B, Gukasyan J, Shintaku IP, Slamon D, Dubinett S, Goldman JW, Elashoff D, Hellmann MD, Ribas A, Garon EB. Tumor Characteristics Associated with Benefit from Pembrolizumab in Advanced Non-Small Cell Lung Cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2019.
  52. Beane JE, Mazzilli SA, Campbell JD, Duclos G, Krysan K, Moy C, Perdomo C, Schaffer M, Liu G, Zhang S, Liu H, Vick J, Dhillon SS, Platero SJ, Dubinett SM, Stevenson C, Reid ME, Lenburg ME, Spira AE. Molecular subtyping reveals immune alterations associated with progression of bronchial premalignant lesions.. Nature communications, 2019.
  53. Salehi-Rad R, Dubinett SM. Understanding the mechanisms of immune-evasion by lung cancer in the context of chronic inflammation in emphysema.. Journal of thoracic disease, 2019.
  54. Scafoglio CR, Villegas B, Abdelhady G, Bailey ST, Liu J, Shirali AS, Wallace WD, Magyar CE, Grogan TR, Elashoff D, Walser T, Yanagawa J, Aberle DR, Barrio JR, Dubinett SM, Shackelford DB. Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma.. Science translational medicine, 2018.
  55. Salehi-Rad R, Dubinett SM. Understanding the Hurdles in Lung Cancer Immunotherapy in the Context of Chronic Obstructive Pulmonary Disease.. American journal of respiratory and critical care medicine, 2018.
  56. Dhar M, Lam JN, Walser T, Dubinett SM, Rettig MB, Di Carlo D. Functional profiling of circulating tumor cells with an integrated vortex capture and single-cell protease activity assay.. Proceedings of the National Academy of Sciences of the United States of America, 2018.
  57. Brahmer JR, Govindan R, Anders RA, Antonia SJ, Sagorsky S, Davies MJ, Dubinett SM, Ferris A, Gandhi L, Garon EB, Hellmann MD, Hirsch FR, Malik S, Neal JW, Papadimitrakopoulou VA, Rimm DL, Schwartz LH, Sepesi B, Yeap BY, Rizvi NA, Herbst RS. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).. Journal for immunotherapy of cancer, 2018.
  58. Garon EB, Siegfried JM, Stabile LP, Young PA, Marquez-Garban DC, Park DJ, Patel R, Hu EH, Sadeghi S, Parikh RJ, Reckamp KL, Adams B, Elashoff RM, Elashoff D, Grogan T, Wang HJ, Dacic S, Brennan M, Valdes Y, Davenport S, Dubinett SM, Press MF, Slamon DJ, Pietras RJ. Randomized phase II study of fulvestrant and erlotinib compared with erlotinib alone in patients with advanced or metastatic non-small cell lung cancer.. Lung cancer (Amsterdam, Netherlands), 2018.
  59. Chattopadhyay A, Yang X, Mukherjee P, Sulaiman D, Fogelman HR, Grijalva V, Dubinett S, Wasler TC, Paul MK, Salehi-Rad R, Mack JJ, Iruela-Arispe ML, Navab M, Fogelman AM, Reddy ST. Treating the Intestine with Oral ApoA-I Mimetic Tg6F Reduces Tumor Burden in Mouse Models of Metastatic Lung Cancer.. Scientific reports, 2018.
  60. Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Braas D, Go J, Graeber TG, Parlati F, Demo S, Li R, Walser TC, Gricowski M, Shuman R, Ibarra J, Fridman D, Phelps ME, Badran K, St John M, Bernthal NM, Federman N, Yanagawa J, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma.. Cancer cell, 2018.
  61. Pine PS, Lund SP, Parsons JR, Vang LK, Mahabal AA, Cinquini L, Kelly SC, Kincaid H, Crichton DJ, Spira A, Liu G, Gower AC, Pass HI, Goparaju C, Dubinett SM, Krysan K, Stass SA, Kukuruga D, Van Keuren-Jensen K, Courtright-Lim A, Thompson KL, Rosenzweig BA, Sorbara L, Srivastava S, Salit ML. Summarizing performance for genome scale measurement of miRNA: reference samples and metrics.. BMC genomics, 2018.
  62. Walser TC, Jing Z, Tran LM, Lin YQ, Yakobian N, Wang G, Krysan K, Zhu LX, Sharma S, Lee MH, Belperio JA, Ooi AT, Gomperts BN, Shay JW, Larsen JE, Minna JD, Hong LS, Fishbein MC, Dubinett SM. Silencing the Snail-Dependent RNA Splice Regulator ESRP1 Drives Malignant Transformation of Human Pulmonary Epithelial Cells.. Cancer research, 2018.
  63. Dubinett SM, Spira AE. Impact of Chronic Obstructive Pulmonary Disease on Immune-based Treatment for Lung Cancer. Moving toward Disease Interception.. American journal of respiratory and critical care medicine, 2018.
  64. Sivakumar S, Lucas FAS, McDowell TL, Lang W, Xu L, Fujimoto J, Zhang J, Futreal PA, Fukuoka J, Yatabe Y, Dubinett SM, Spira AE, Fowler J, Hawk ET, Wistuba II, Scheet P, Kadara H. Genomic Landscape of Atypical Adenomatous Hyperplasia Reveals Divergent Modes to Lung Adenocarcinoma.. Cancer research, 2017.
  65. Hocker JR, Deb SJ, Li M, Lerner MR, Lightfoot SA, Quillet AA, Hanas RJ, Reinersman M, Thompson JL, Vu NT, Kupiec TC, Brackett DJ, Peyton MD, Dubinett SM, Burkhart HM, Postier RG, Hanas JS. Serum Monitoring and Phenotype Identification of Stage I Non-Small Cell Lung Cancer Patients.. Cancer investigation, 2017.
  66. Pellionisz PA, Lin Y, Mallen-St Clair J, Luo J, Suwarnasarn A, Schaue D, Elashoff DA, Palma-Diaz F, Dubinett SM, Sharma S, Wu B, St John MA. Use of a Novel Polymer in an Animal Model of Head and Neck Squamous Cell Carcinoma.. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2017.
  67. Pavel AB, Campbell JD, Liu G, Elashoff D, Dubinett S, Smith K, Whitney D, Lenburg ME, Spira A, AEGIS Study Team. Alterations in Bronchial Airway miRNA Expression for Lung Cancer Detection.. Cancer prevention research (Philadelphia, Pa.), 2017.
  68. Pagano PC, Tran LM, Bendris N, O'Byrne S, Tse HT, Sharma S, Hoech JW, Park SJ, Liclican EL, Jing Z, Li R, Krysan K, Paul MK, Fontebasso Y, Larsen JE, Hakimi S, Seki A, Fishbein MC, Gimzewski JK, Carlo DD, Minna JD, Walser TC, Dubinett SM. Identification of a Human Airway Epithelial Cell Subpopulation with Altered Biophysical, Molecular, and Metastatic Properties.. Cancer prevention research (Philadelphia, Pa.), 2017.
  69. Lee JM, Lee MH, Garon E, Goldman JW, Salehi-Rad R, Baratelli FE, Schaue D, Wang G, Rosen F, Yanagawa J, Walser TC, Lin Y, Park SJ, Adams S, Marincola FM, Tumeh PC, Abtin F, Suh R, Reckamp KL, Lee G, Wallace WD, Lee S, Zeng G, Elashoff DA, Sharma S, Dubinett SM. Phase I Trial of Intratumoral Injection of CCL21 Gene-Modified Dendritic Cells in Lung Cancer Elicits Tumor-Specific Immune Responses and CD8+ T-cell Infiltration.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2017.
  70. Kang S, Li Q, Chen Q, Zhou Y, Park S, Lee G, Grimes B, Krysan K, Yu M, Wang W, Alber F, Sun F, Dubinett SM, Li W, Zhou XJ. CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA.. Genome biology, 2017.
  71. Momcilovic M, Bailey ST, Lee JT, Fishbein MC, Magyar C, Braas D, Graeber T, Jackson NJ, Czernin J, Emberley E, Gross M, Janes J, Mackinnon A, Pan A, Rodriguez M, Works M, Zhang W, Parlati F, Demo S, Garon E, Krysan K, Walser TC, Dubinett SM, Sadeghi S, Christofk HR, Shackelford DB. Targeted Inhibition of EGFR and Glutaminase Induces Metabolic Crisis in EGFR Mutant Lung Cancer.. Cell reports, 2017.
  72. van Draanen J, Davidson P, Bour-Jordan H, Bowman-Carpio L, Boyle D, Dubinett S, Gardner B, Gardner J, McFall C, Mercola D, Nakazono T, Soares S, Stoppler H, Tempero M, Vandenberg S, Wan YJ, Dry S. Assessing Researcher Needs for a Virtual Biobank.. Biopreservation and biobanking, 2016.
  73. Arenberg D, Dubinett SM. Lung Cancer: Evolving Concepts in Management.. Seminars in respiratory and critical care medicine, 2016.
  74. Moses E, Wang T, Corbett S, Jackson GR, Drizik E, Perdomo C, Perdomo C, Kleerup E, Brooks D, O'Connor G, Dubinett S, Hayden P, Lenburg ME, Spira A. Molecular Impact of Electronic Cigarette Aerosol Exposure in Human Bronchial Epithelium.. Toxicological sciences : an official journal of the Society of Toxicology, 2016.
  75. Lin Y, Mallen-St Clair J, Wang G, Luo J, Palma-Diaz F, Lai C, Elashoff DA, Sharma S, Dubinett SM, St John M. p38 MAPK mediates epithelial-mesenchymal transition by regulating p38IP and Snail in head and neck squamous cell carcinoma.. Oral oncology, 2016.
  76. Hong CS, Graham NA, Gu W, Espindola Camacho C, Mah V, Maresh EL, Alavi M, Bagryanova L, Krotee PAL, Gardner BK, Behbahan IS, Horvath S, Chia D, Mellinghoff IK, Hurvitz SA, Dubinett SM, Critchlow SE, Kurdistani SK, Goodglick L, Braas D, Graeber TG, Christofk HR. MCT1 Modulates Cancer Cell Pyruvate Export and Growth of Tumors that Co-express MCT1 and MCT4.. Cell reports, 2016.
  77. Momcilovic M, McMickle R, Abt E, Seki A, Simko SA, Magyar C, Stout DB, Fishbein MC, Walser TC, Dubinett SM, Shackelford DB. Heightening Energetic Stress Selectively Targets LKB1-Deficient Non-Small Cell Lung Cancers.. Cancer research, 2015.
  78. Lin Y, Mallen-St Clair J, Luo J, Sharma S, Dubinett S, St John M. p53 modulates NF-κB mediated epithelial-to-mesenchymal transition in head and neck squamous cell carcinoma.. Oral oncology, 2015.
  79. Reckamp KL, Koczywas M, Cristea MC, Dowell JE, Wang HJ, Gardner BK, Milne GL, Figlin RA, Fishbein MC, Elashoff RM, Dubinett SM. Randomized phase 2 trial of erlotinib in combination with high-dose celecoxib or placebo in patients with advanced non-small cell lung cancer.. Cancer, 2015.
  80. Zhu LX, Davoodi M, Srivastava MK, Kachroo P, Lee JM, St John M, Harris-White M, Huang M, Strieter RM, Dubinett S, Sharma S. GITR agonist enhances vaccination responses in lung cancer.. Oncoimmunology, 2015.
  81. Fontebasso Y, Dubinett SM. Drug Development for Metastasis Prevention.. Critical reviews in oncogenesis, 2015.
  82. Lee MH, Kachroo P, Pagano PC, Yanagawa J, Wang G, Walser TC, Krysan K, Sharma S, John MS, Dubinett SM, Lee JM. Combination Treatment with Apricoxib and IL-27 Enhances Inhibition of Epithelial-Mesenchymal Transition in Human Lung Cancer Cells through a STAT1 Dominant Pathway.. Journal of cancer science & therapy, 2014.
  83. Liclican EL, Walser TC, Hazra S, Krysan K, Park SJ, Pagano PC, Gardner BK, Larsen JE, Minna JD, Dubinett SM. Loss of miR125a expression in a model of K-ras-dependent pulmonary premalignancy.. Cancer prevention research (Philadelphia, Pa.), 2014.
  84. Lin Y, Luo J, Zhu WE, Srivastava M, Schaue D, Elashoff DA, Dubinett SM, Sharma S, Wu B, St John MA. A cytokine-delivering polymer is effective in reducing tumor burden in a head and neck squamous cell carcinoma murine model.. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2014.
  85. Ooi AT, Gower AC, Zhang KX, Vick JL, Hong L, Nagao B, Wallace WD, Elashoff DA, Walser TC, Dubinett SM, Pellegrini M, Lenburg ME, Spira A, Gomperts BN. Molecular profiling of premalignant lesions in lung squamous cell carcinomas identifies mechanisms involved in stepwise carcinogenesis.. Cancer prevention research (Philadelphia, Pa.), 2014.
  86. Hanas JS, Peyton MD, Lerner MR, Lightfoot SA, Deb SJ, Hanas RJ, Vu NT, Kupiec TC, Stowell DE, Brackett DJ, Dubinett SM, Hocker JR. Distinguishing patients with stage I lung cancer versus control individuals using serum mass profiling.. Cancer investigation, 2014.
  87. Krysan K, Kusko R, Grogan T, O'Hearn J, Reckamp KL, Walser TC, Garon EB, Lenburg ME, Sharma S, Spira AE, Elashoff D, Dubinett SM. PGE2-driven expression of c-Myc and oncomiR-17-92 contributes to apoptosis resistance in NSCLC.. Molecular cancer research : MCR, 2014.
  88. Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, Hong CS, Kamranpour N, Pitts S, Kabbinavar F, Patel C, von Euw E, Black A, Michelakis ED, Dubinett SM, Slamon DJ. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced non-small cell lung cancer.. Journal of cancer research and clinical oncology, 2014.
  89. Kachroo P, Lee MH, Zhang L, Baratelli F, Lee G, Srivastava MK, Wang G, Walser TC, Krysan K, Sharma S, Dubinett SM, Lee JM. IL-27 inhibits epithelial-mesenchymal transition and angiogenic factor production in a STAT1-dominant pathway in human non-small cell lung cancer.. Journal of experimental & clinical cancer research : CR, 2013.
  90. Grant JL, Fishbein MC, Hong LS, Krysan K, Minna JD, Shay JW, Walser TC, Dubinett SM. A novel molecular pathway for Snail-dependent, SPARC-mediated invasion in non-small cell lung cancer pathogenesis.. Cancer prevention research (Philadelphia, Pa.), 2013.
  91. Perdomo C, Campbell JD, Gerrein J, Tellez CS, Garrison CB, Walser TC, Drizik E, Si H, Gower AC, Vick J, Anderlind C, Jackson GR, Mankus C, Schembri F, O'Hara C, Gomperts BN, Dubinett SM, Hayden P, Belinsky SA, Lenburg ME, Spira A. MicroRNA 4423 is a primate-specific regulator of airway epithelial cell differentiation and lung carcinogenesis.. Proceedings of the National Academy of Sciences of the United States of America, 2013.
  92. Ofili EO, Fair A, Norris K, Verbalis JG, Poland R, Bernard G, Stephens DS, Dubinett SM, Imperato-McGinley J, Dottin RP, Pulley J, West A, Brown A, Mellman TA. Models of interinstitutional partnerships between research intensive universities and minority serving institutions (MSI) across the Clinical Translational Science Award (CTSA) consortium.. Clinical and translational science, 2013.
  93. Dubinett SM, Spira A. Challenge and opportunity of targeted lung cancer chemoprevention.. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013.
  94. Krysan K, Cui X, Gardner BK, Reckamp KL, Wang X, Hong L, Walser TC, Rodriguez NL, Pagano PC, Garon EB, Brothers JF, Elashoff D, Lee JM, Spira AE, Sharma S, Fishbein MC, Dubinett SM. Elevated neutrophil gelatinase-associated lipocalin contributes to erlotinib resistance in non-small cell lung cancer.. American journal of translational research, 2013.
  95. Liao W, Jordaan G, Srivastava MK, Dubinett S, Sharma S, Sharma S. Effect of epigenetic histone modifications on E-cadherin splicing and expression in lung cancer.. American journal of cancer research, 2013.
  96. Ohashi K, Sequist LV, Arcila ME, Lovly CM, Chen X, Rudin CM, Moran T, Camidge DR, Vnencak-Jones CL, Berry L, Pan Y, Sasaki H, Engelman JA, Garon EB, Dubinett SM, Franklin WA, Riely GJ, Sos ML, Kris MG, Dias-Santagata D, Ladanyi M, Bunn PA, Pao W. Characteristics of lung cancers harboring NRAS mutations.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2013.
  97. Sharma S, Zhu L, Davoodi M, Harris-White M, Lee JM, St John M, Salgia R, Dubinett S. TLR3 agonists and proinflammatory antitumor activities.. Expert opinion on therapeutic targets, 2013.
  98. Garon EB, Finn RS, Hamidi H, Dering J, Pitts S, Kamranpour N, Desai AJ, Hosmer W, Ide S, Avsar E, Jensen MR, Quadt C, Liu M, Dubinett SM, Slamon DJ. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.. Molecular cancer therapeutics, 2013.
  99. Garon EB, Pietras RJ, Finn RS, Kamranpour N, Pitts S, Márquez-Garbán DC, Desai AJ, Dering J, Hosmer W, von Euw EM, Dubinett SM, Slamon DJ. Antiestrogen fulvestrant enhances the antiproliferative effects of epidermal growth factor receptor inhibitors in human non-small-cell lung cancer.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2013.
  100. Sharma S, Zhu L, Srivastava MK, Harris-White M, Huang M, Lee JM, Rosen F, Lee G, Wang G, Kickhoefer V, Rome LH, Baratelli F, St John M, Reckamp K, Chul-Yang S, Hillinger S, Strieter R, Dubinett S. CCL21 Chemokine Therapy for Lung Cancer.. International trends in immunity, 2013.
  101. Gomperts BN, Walser TC, Spira A, Dubinett SM. Enriching the molecular definition of the airway "field of cancerization:" establishing new paradigms for the patient at risk for lung cancer.. Cancer prevention research (Philadelphia, Pa.), 2012.
  102. Srivastava MK, Dubinett S, Sharma S. Targeting MDSCs enhance therapeutic vaccination responses against lung cancer.. Oncoimmunology, 2012.
  103. Sharma S, Dubinett S, Salgia R. CD14(+)S100A9(+) myeloid-derived suppressor cells portend decreased survival in patients with advanced lung cancer.. American journal of respiratory and critical care medicine, 2012.
  104. Lu QY, Jin Y, Mao JT, Zhang ZF, Heber D, Dubinett SM, Rao J. Green tea inhibits cycolooxygenase-2 in non-small cell lung cancer cells through the induction of Annexin-1.. Biochemical and biophysical research communications, 2012.
  105. Srivastava MK, Zhu L, Harris-White M, Huang M, St John M, Lee JM, Salgia R, Cameron RB, Strieter R, Dubinett S, Sharma S. Targeting myeloid-derived suppressor cells augments antitumor activity against lung cancer.. ImmunoTargets and therapy, 2012.
  106. St John MA, Wang G, Luo J, Dohadwala M, Hu D, Lin Y, Dennis M, Lee JM, Elashoff D, Lawhon T, Zaknoen SL, Burrows FJ, Dubinett SM. Apricoxib upregulates 15-PGDH and PGT in tobacco-related epithelial malignancies.. British journal of cancer, 2012.
  107. Srivastava MK, Zhu L, Harris-White M, Kar UK, Kar U, Huang M, Johnson MF, Lee JM, Elashoff D, Strieter R, Dubinett S, Sharma S. Myeloid suppressor cell depletion augments antitumor activity in lung cancer.. PloS one, 2012.
  108. Dennis M, Wang G, Luo J, Lin Y, Dohadwala M, Abemayor E, Elashoff DA, Sharma S, Dubinett SM, St John MA. Snail controls the mesenchymal phenotype and drives erlotinib resistance in oral epithelial and head and neck squamous cell carcinoma cells.. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2012.
  109. Hu D, Lau OD, Wang L, Wang G, Schaue D, Zhu L, Huang M, Lin Y, Dennis M, Abemayor E, Elashoff DA, Dubinett SM, McBride WH, Sharma S, Wu B, St John MA. A novel modular polymer platform for the treatment of head and neck squamous cell carcinoma in an animal model.. Archives of otolaryngology--head & neck surgery, 2012.
  110. CTSA Principal Investigators, Shamoon H, Center D, Davis P, Tuchman M, Ginsberg H, Califf R, Stephens D, Mellman T, Verbalis J, Nadler L, Shekhar A, Ford D, Rizza R, Shaker R, Brady K, Murphy B, Cronstein B, Hochman J, Greenland P, Orwoll E, Sinoway L, Greenberg H, Jackson R, Coller B, Topol E, Guay-Woodford L, Runge M, Clark R, McClain D, Selker H, Lowery C, Dubinett S, Berglund L, Cooper D, Firestein G, Johnston SC, Solway J, Heubi J, Sokol R, Nelson D, Tobacman L, Rosenthal G, Aaronson L, Barohn R, Kern P, Sullivan J, Shanley T, Blazar B, Larson R, FitzGerald G, Reis S, Pearson T, Buchanan T, McPherson D, Brasier A, Toto R, Disis M, Drezner M, Bernard G, Clore J, Evanoff B, Imperato-McGinley J, Sherwin R, Pulley J. Preparedness of the CTSA's structural and scientific assets to support the mission of the National Center for Advancing Translational Sciences (NCATS).. Clinical and translational science, 2012.
  111. Srivastava MK, Andersson Å, Zhu L, Harris-White M, Lee JM, Dubinett S, Sharma S. Myeloid suppressor cells and immune modulation in lung cancer.. Immunotherapy, 2012.
  112. Huynh TP, Mah V, Sampson VB, Chia D, Fishbein MC, Horvath S, Alavi M, Wu DC, Harper J, Sarafian T, Dubinett SM, Langhans SA, Goodglick L, Rajasekaran AK. Na,K-ATPase is a target of cigarette smoke and reduced expression predicts poor patient outcome of smokers with lung cancer.. American journal of physiology. Lung cellular and molecular physiology, 2012.
  113. Garon EB, Dubinett SM. Mitotic inhibitors.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2011.
  114. Heinrich EL, Walser TC, Krysan K, Liclican EL, Grant JL, Rodriguez NL, Dubinett SM. The inflammatory tumor microenvironment, epithelial mesenchymal transition and lung carcinogenesis.. Cancer microenvironment : official journal of the International Cancer Microenvironment Society, 2011.
  115. Sharma S, Srivastava MK, Harris-White M, Lee JM, Dubinett S. MUC1 peptide vaccine mediated antitumor activity in non-small cell lung cancer.. Expert opinion on biological therapy, 2011.
  116. Stoyanov E, Uddin M, Mankuta D, Dubinett SM, Levi-Schaffer F. Mast cells and histamine enhance the proliferation of non-small cell lung cancer cells.. Lung cancer (Amsterdam, Netherlands), 2011.
  117. Mao JT, Roth MD, Fishbein MC, Aberle DR, Zhang ZF, Rao JY, Tashkin DP, Goodglick L, Holmes EC, Cameron RB, Dubinett SM, Elashoff R, Szabo E, Elashoff D. Lung cancer chemoprevention with celecoxib in former smokers.. Cancer prevention research (Philadelphia, Pa.), 2011.
  118. National Lung Screening Trial Research Team, Aberle DR, Adams AM, Berg CD, Black WC, Clapp JD, Fagerstrom RM, Gareen IF, Gatsonis C, Marcus PM, Sicks JD. Reduced lung-cancer mortality with low-dose computed tomographic screening.. The New England journal of medicine, 2011.
  119. Andersson A, Srivastava MK, Harris-White M, Huang M, Zhu L, Elashoff D, Strieter RM, Dubinett SM, Sharma S. Role of CXCR3 ligands in IL-7/IL-7R alpha-Fc-mediated antitumor activity in lung cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2011.
  120. Al-Shyoukh I, Yu F, Feng J, Yan K, Dubinett S, Ho CM, Shamma JS, Sun R. Systematic quantitative characterization of cellular responses induced by multiple signals.. BMC systems biology, 2011.
  121. Kar UK, Srivastava MK, Andersson A, Baratelli F, Huang M, Kickhoefer VA, Dubinett SM, Rome LH, Sharma S. Novel CCL21-vault nanocapsule intratumoral delivery inhibits lung cancer growth.. PloS one, 2011.
  122. Gomperts BN, Spira A, Massion PP, Walser TC, Wistuba II, Minna JD, Dubinett SM. Evolving concepts in lung carcinogenesis.. Seminars in respiratory and critical care medicine, 2011.
  123. Lee G, Gardner BK, Elashoff DA, Purcell CM, Sandha HS, Mao JT, Krysan K, Lee JM, Dubinett SM. Elevated levels of CXC chemokine connective tissue activating peptide (CTAP)-III in lung cancer patients.. American journal of translational research, 2011.
  124. Mendelsohn AH, Lai CK, Shintaku IP, Fishbein MC, Brugman K, Elashoff DA, Abemayor E, Dubinett SM, St John MA. Snail as a novel marker for regional metastasis in head and neck squamous cell carcinoma.. American journal of otolaryngology, 2011.
  125. Mortazavi F, Dubinett S, Rettig M. c-Crk proto-oncogene contributes to transcriptional repression of p120-catenin in non-small cell lung cancer cells.. Clinical & experimental metastasis, 2011.
  126. Hosmer WD, Dubinett SM, Garon EB. Novel drugs--miscellaneous category.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010.
  127. Garon EB, Dubinett SM. Poly(ADP-ribose) polymerase inhibitors.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010.
  128. Patz EF, Caporaso NE, Dubinett SM, Massion PP, Hirsch FR, Minna JD, Gatsonis C, Duan F, Adams A, Apgar C, Medina RM, Aberle DR. National Lung Cancer Screening Trial American College of Radiology Imaging Network Specimen Biorepository originating from the Contemporary Screening for the Detection of Lung Cancer Trial (NLST, ACRIN 6654): design, intent, and availability of specimens for validation of lung cancer biomarkers.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2010.
  129. Mendelsohn AH, Lai CK, Shintaku IP, Elashoff DA, Dubinett SM, Abemayor E, St John MA. Histopathologic findings of HPV and p16 positive HNSCC.. The Laryngoscope, 2010.
  130. Ooi AT, Mah V, Nickerson DW, Gilbert JL, Ha VL, Hegab AE, Horvath S, Alavi M, Maresh EL, Chia D, Gower AC, Lenburg ME, Spira A, Solis LM, Wistuba II, Walser TC, Wallace WD, Dubinett SM, Goodglick L, Gomperts BN. Presence of a putative tumor-initiating progenitor cell population predicts poor prognosis in smokers with non-small cell lung cancer.. Cancer research, 2010.
  131. Dubinett SM, Lee JM, Sharma S, Mulé JJ. Chemokines: can effector cells be redirected to the site of the tumor?. Cancer journal (Sudbury, Mass.), 2010.
  132. Baratelli F, Lee JM, Hazra S, Lin Y, Walser TC, Schaue D, Pak PS, Elashoff D, Reckamp K, Zhang L, Fishbein MC, Sharma S, Dubinett SM. PGE(2) contributes to TGF-beta induced T regulatory cell function in human non-small cell lung cancer.. American journal of translational research, 2010.
  133. Mortazavi F, An J, Dubinett S, Rettig M. p120-catenin is transcriptionally downregulated by FOXC2 in non-small cell lung cancer cells.. Molecular cancer research : MCR, 2010.
  134. Demaria S, Pikarsky E, Karin M, Coussens LM, Chen YC, El-Omar EM, Trinchieri G, Dubinett SM, Mao JT, Szabo E, Krieg A, Weiner GJ, Fox BA, Coukos G, Wang E, Abraham RT, Carbone M, Lotze MT. Cancer and inflammation: promise for biologic therapy.. Journal of immunotherapy (Hagerstown, Md. : 1997), 2010.
  135. Dohadwala M, Wang G, Heinrich E, Luo J, Lau O, Shih H, Munaim Q, Lee G, Hong L, Lai C, Abemayor E, Fishbein MC, Elashoff DA, Dubinett SM, St John MA. The role of ZEB1 in the inflammation-induced promotion of EMT in HNSCC.. Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery, 2010.
  136. Gomperts BN, Spira A, Elashoff DE, Dubinett SM. Lung cancer biomarkers: FISHing in the sputum for risk assessment and early detection.. Cancer prevention research (Philadelphia, Pa.), 2010.
  137. Yanagawa J, Walser TC, Zhu LX, Hong L, Fishbein MC, Mah V, Chia D, Goodglick L, Elashoff DA, Luo J, Magyar CE, Dohadwala M, Lee JM, St John MA, Strieter RM, Sharma S, Dubinett SM. Snail promotes CXCR2 ligand-dependent tumor progression in non-small cell lung carcinoma.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009.
  138. Garon EB, Dubinett SM. Intracellular signaling molecules.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2009.
  139. St John MA, Dohadwala M, Luo J, Wang G, Lee G, Shih H, Heinrich E, Krysan K, Walser T, Hazra S, Zhu L, Lai C, Abemayor E, Fishbein M, Elashoff DA, Sharma S, Dubinett SM. Proinflammatory mediators upregulate snail in head and neck squamous cell carcinoma.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009.
  140. Limsukon A, Susanto I, Soo Hoo GW, Dubinett SM, Batra RK. Regression of recurrent respiratory papillomatosis with celecoxib and erlotinib combination therapy.. Chest, 2009.
  141. Lee WH, Hung MC, Iczkowski KA, Languino LR, Dubinett SM, Wang D. The launch of the american journal of translational research.. American journal of translational research, 2009.
  142. Dubinett S, Sharma S. Towards effective immunotherapy for lung cancer: simultaneous targeting of tumor-initiating cells and immune pathways in the tumor microenvironment.. Immunotherapy, 2009.
  143. Lee G, Walser TC, Dubinett SM. Chronic inflammation, chronic obstructive pulmonary disease, and lung cancer.. Current opinion in pulmonary medicine, 2009.
  144. Reckamp KL, Figlin RA, Burdick MD, Dubinett SM, Elashoff RM, Strieter RM. CXCR4 expression on circulating pan-cytokeratin positive cells is associated with survival in patients with advanced non-small cell lung cancer.. BMC cancer, 2009.
  145. Andersson A, Yang SC, Huang M, Zhu L, Kar UK, Batra RK, Elashoff D, Strieter RM, Dubinett SM, Sharma S. IL-7 promotes CXCR3 ligand-dependent T cell antitumor reactivity in lung cancer.. Journal of immunology (Baltimore, Md. : 1950), 2009.
  146. Punturieri A, Szabo E, Croxton TL, Shapiro SD, Dubinett SM. Lung cancer and chronic obstructive pulmonary disease: needs and opportunities for integrated research.. Journal of the National Cancer Institute, 2009.
  147. Lu QY, Yang Y, Jin YS, Zhang ZF, Heber D, Li FP, Dubinett SM, Sondej MA, Loo JA, Rao JY. Effects of green tea extract on lung cancer A549 cells: proteomic identification of proteins associated with cell migration.. Proteomics, 2009.
  148. Walser T, Cui X, Yanagawa J, Lee JM, Heinrich E, Lee G, Sharma S, Dubinett SM. Smoking and lung cancer: the role of inflammation.. Proceedings of the American Thoracic Society, 2008.
  149. Dubinett SM, Aberle DR, Tashkin DP, Mao JT. The partners--airflow obstruction, emphysema, and lung cancer.. American journal of respiratory and critical care medicine, 2008.
  150. Dubinett SM, Mao JT, Hazra S. Focusing downstream in lung cancer prevention: 15-hydroxyprostaglandin dehydrogenase.. Cancer prevention research (Philadelphia, Pa.), 2008.
  151. Baratelli F, Takedatsu H, Hazra S, Peebles K, Luo J, Kurimoto PS, Zeng G, Batra RK, Sharma S, Dubinett SM, Lee JM. Pre-clinical characterization of GMP grade CCL21-gene modified dendritic cells for application in a phase I trial in non-small cell lung cancer.. Journal of translational medicine, 2008.
  152. Einhorn LH, Bonomi P, Bunn PA, Camidge DR, Carbone DP, Choy H, Dubinett SM, Gandara DR, Gaspar LE, Govindan R, Johnson DH, Minna JD, Scagliotti G, West HJ, Herbst RS. Summary report 7th Annual Targeted Therapies of the Treatment of Lung Cancer.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008.
  153. Lee JM, Yanagawa J, Peebles KA, Sharma S, Mao JT, Dubinett SM. Inflammation in lung carcinogenesis: new targets for lung cancer chemoprevention and treatment.. Critical reviews in oncology/hematology, 2008.
  154. Su H, Seimbille Y, Ferl GZ, Bodenstein C, Fueger B, Kim KJ, Hsu YT, Dubinett SM, Phelps ME, Czernin J, Weber WA. Evaluation of [(18)F]gefitinib as a molecular imaging probe for the assessment of the epidermal growth factor receptor status in malignant tumors.. European journal of nuclear medicine and molecular imaging, 2008.
  155. Krysan K, Lee JM, Dohadwala M, Gardner BK, Reckamp KL, Garon E, St John M, Sharma S, Dubinett SM. Inflammation, epithelial to mesenchymal transition, and epidermal growth factor receptor tyrosine kinase inhibitor resistance.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008.
  156. Reckamp KL, Gardner BK, Figlin RA, Elashoff D, Krysan K, Dohadwala M, Mao J, Sharma S, Inge L, Rajasekaran A, Dubinett SM. Tumor response to combination celecoxib and erlotinib therapy in non-small cell lung cancer is associated with a low baseline matrix metalloproteinase-9 and a decline in serum-soluble E-cadherin.. Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer, 2008.
  157. Hazra S, Peebles KA, Sharma S, Mao JT, Dubinett SM. The Role of PPARgamma in the Cyclooxygenase Pathway in Lung Cancer.. PPAR research, 2008.
  158. Peebles KA, Lee JM, Mao JT, Hazra S, Reckamp KL, Krysan K, Dohadwala M, Heinrich EL, Walser TC, Cui X, Baratelli FE, Garon E, Sharma S, Dubinett SM. Inflammation and lung carcinogenesis: applying findings in prevention and treatment.. Expert review of anticancer therapy, 2007.
  159. Hazra S, Dubinett SM. Ciglitazone mediates COX-2 dependent suppression of PGE2 in human non-small cell lung cancer cells.. Prostaglandins, leukotrienes, and essential fatty acids, 2007.
  160. Liu M, Yang SC, Sharma S, Luo J, Cui X, Peebles KA, Huang M, Sato M, Ramirez RD, Shay JW, Minna JD, Dubinett SM. EGFR signaling is required for TGF-beta 1 mediated COX-2 induction in human bronchial epithelial cells.. American journal of respiratory cell and molecular biology, 2007.
  161. Hazra S, Batra RK, Tai HH, Sharma S, Cui X, Dubinett SM. Pioglitazone and rosiglitazone decrease prostaglandin E2 in non-small-cell lung cancer cells by up-regulating 15-hydroxyprostaglandin dehydrogenase.. Molecular pharmacology, 2007.
  162. Lee JM, Mao JT, Krysan K, Dubinett SM. Significance of cyclooxygenase-2 in prognosis, targeted therapy and chemoprevention of NSCLC.. Future oncology (London, England), 2007.
  163. Lu QY, Jin YS, Zhang ZF, Le AD, Heber D, Li FP, Dubinett SM, Rao JY. Green tea induces annexin-I expression in human lung adenocarcinoma A549 cells: involvement of annexin-I in actin remodeling.. Laboratory investigation; a journal of technical methods and pathology, 2007.
  164. Feeley BT, Liu NQ, Conduah AH, Krenek L, Roth K, Dougall WC, Huard J, Dubinett S, Lieberman JR. Mixed metastatic lung cancer lesions in bone are inhibited by noggin overexpression and Rank:Fc administration.. Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research, 2006.
  165. Su H, Bodenstein C, Dumont RA, Seimbille Y, Dubinett S, Phelps ME, Herschman H, Czernin J, Weber W. Monitoring tumor glucose utilization by positron emission tomography for the prediction of treatment response to epidermal growth factor receptor kinase inhibitors.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006.
  166. Zeng G, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y, Rao J, Li W, Chen D, Langford MP, Duggan C, Belldegrun AS, Dubinett SM. Dendritic cell surface calreticulin is a receptor for NY-ESO-1: direct interactions between tumor-associated antigen and the innate immune system.. Journal of immunology (Baltimore, Md. : 1950), 2006.
  167. Kelloff GJ, Lippman SM, Dannenberg AJ, Sigman CC, Pearce HL, Reid BJ, Szabo E, Jordan VC, Spitz MR, Mills GB, Papadimitrakopoulou VA, Lotan R, Aggarwal BB, Bresalier RS, Kim J, Arun B, Lu KH, Thomas ME, Rhodes HE, Brewer MA, Follen M, Shin DM, Parnes HL, Siegfried JM, Evans AA, Blot WJ, Chow WH, Blount PL, Maley CC, Wang KK, Lam S, Lee JJ, Dubinett SM, Engstrom PF, Meyskens FL, O'Shaughnessy J, Hawk ET, Levin B, Nelson WG, Hong WK, AACR Task Force on Cancer Prevention. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer--a plan to move forward.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006.
  168. Reckamp KL, Krysan K, Morrow JD, Milne GL, Newman RA, Tucker C, Elashoff RM, Dubinett SM, Figlin RA. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006.
  169. Dohadwala M, Yang SC, Luo J, Sharma S, Batra RK, Huang M, Lin Y, Goodglick L, Krysan K, Fishbein MC, Hong L, Lai C, Cameron RB, Gemmill RM, Drabkin HA, Dubinett SM. Cyclooxygenase-2-dependent regulation of E-cadherin: prostaglandin E(2) induces transcriptional repressors ZEB1 and snail in non-small cell lung cancer.. Cancer research, 2006.
  170. Krysan K, Reckamp KL, Sharma S, Dubinett SM. The potential and rationale for COX-2 inhibitors in lung cancer.. Anti-cancer agents in medicinal chemistry, 2006.
  171. Cui X, Yang SC, Sharma S, Heuze-Vourc'h N, Dubinett SM. IL-4 regulates COX-2 and PGE2 production in human non-small cell lung cancer.. Biochemical and biophysical research communications, 2006.
  172. Yang SC, Batra RK, Hillinger S, Reckamp KL, Strieter RM, Dubinett SM, Sharma S. Intrapulmonary administration of CCL21 gene-modified dendritic cells reduces tumor burden in spontaneous murine bronchoalveolar cell carcinoma.. Cancer research, 2006.
  173. Hoang B, Zhu L, Shi Y, Frost P, Yan H, Sharma S, Sharma S, Goodglick L, Dubinett S, Lichtenstein A. Oncogenic RAS mutations in myeloma cells selectively induce cox-2 expression, which participates in enhanced adhesion to fibronectin and chemoresistance.. Blood, 2006.
  174. Pan J, Burdick MD, Belperio JA, Xue YY, Gerard C, Sharma S, Dubinett SM, Strieter RM. CXCR3/CXCR3 ligand biological axis impairs RENCA tumor growth by a mechanism of immunoangiostasis.. Journal of immunology (Baltimore, Md. : 1950), 2006.
  175. Mao JT, Fishbein MC, Adams B, Roth MD, Goodglick L, Hong L, Burdick M, Strieter ER, Holmes C, Tashkin DP, Dubinett SM. Celecoxib decreases Ki-67 proliferative index in active smokers.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006.
  176. Weinberg OK, Marquez-Garban DC, Fishbein MC, Goodglick L, Garban HJ, Dubinett SM, Pietras RJ. Aromatase inhibitors in human lung cancer therapy.. Cancer research, 2005.
  177. Dalwadi H, Krysan K, Heuze-Vourc'h N, Dohadwala M, Elashoff D, Sharma S, Cacalano N, Lichtenstein A, Dubinett S. Cyclooxygenase-2-dependent activation of signal transducer and activator of transcription 3 by interleukin-6 in non-small cell lung cancer.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2005.
  178. Liu W, Dubinett S, Patterson SL, Kelly KA. COX-2 inhibition affects growth rate of Chlamydia muridarum within epithelial cells.. Microbes and infection, 2005.
  179. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB, Gilbert J, Ochoa AC. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.. The Journal of experimental medicine, 2005.
  180. Baratelli F, Lin Y, Zhu L, Yang SC, Heuzé-Vourc'h N, Zeng G, Reckamp K, Dohadwala M, Sharma S, Dubinett SM. Prostaglandin E2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells.. Journal of immunology (Baltimore, Md. : 1950), 2005.
  181. Heuzé-Vourc'h N, Liu M, Dalwadi H, Baratelli FE, Zhu L, Goodglick L, Põld M, Sharma S, Ramirez RD, Shay JW, Minna JD, Strieter RM, Dubinett SM. IL-20, an anti-angiogenic cytokine that inhibits COX-2 expression.. Biochemical and biophysical research communications, 2005.
  182. Sharma S, Zhu L, Yang SC, Zhang L, Lin J, Hillinger S, Gardner B, Reckamp K, Strieter RM, Huang M, Batra RK, Dubinett SM. Cyclooxygenase 2 inhibition promotes IFN-gamma-dependent enhancement of antitumor responses.. Journal of immunology (Baltimore, Md. : 1950), 2005.
  183. Krysan K, Reckamp KL, Dalwadi H, Sharma S, Rozengurt E, Dohadwala M, Dubinett SM. Prostaglandin E2 activates mitogen-activated protein kinase/Erk pathway signaling and cell proliferation in non-small cell lung cancer cells in an epidermal growth factor receptor-independent manner.. Cancer research, 2005.
  184. Mao JT, Cui X, Reckamp K, Liu M, Krysan K, Dalwadi H, Sharma S, Hazra S, Strieter R, Gardner B, Dubinett SM. Chemoprevention strategies with cyclooxygenase-2 inhibitors for lung cancer.. Clinical lung cancer, 2005.
  185. Sharma S, Yang SC, Zhu L, Reckamp K, Gardner B, Baratelli F, Huang M, Batra RK, Dubinett SM. Tumor cyclooxygenase-2/prostaglandin E2-dependent promotion of FOXP3 expression and CD4+ CD25+ T regulatory cell activities in lung cancer.. Cancer research, 2005.
  186. Baratelli F, Krysan K, Heuzé-Vourc'h N, Zhu L, Escuadro B, Sharma S, Reckamp K, Dohadwala M, Dubinett SM. PGE2 confers survivin-dependent apoptosis resistance in human monocyte-derived dendritic cells.. Journal of leukocyte biology, 2005.
  187. Zeng G, Aldridge ME, Wang Y, Pantuck AJ, Wang AY, Liu YX, Han Y, Yuan YH, Robbins PF, Dubinett SM, deKernion JB, Belldegrun AS. Dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: implications as a potential biomarker.. International journal of cancer, 2005.
  188. Gamradt SC, Feeley BT, Liu NQ, Roostaeian J, Lin YQ, Zhu LX, Sharma S, Dubinett SM, Lieberman JR. The effect of cyclooxygenase-2 (COX-2) inhibition on human prostate cancer induced osteoblastic and osteolytic lesions in bone.. Anticancer research, 2005.
  189. Strieter RM, Belperio JA, Burdick MD, Sharma S, Dubinett SM, Keane MP. CXC chemokines: angiogenesis, immunoangiostasis, and metastases in lung cancer.. Annals of the New York Academy of Sciences, 2004.
  190. Baratelli FE, Heuzé-Vourc'h N, Krysan K, Dohadwala M, Riedl K, Sharma S, Dubinett SM. Prostaglandin E2-dependent enhancement of tissue inhibitors of metalloproteinases-1 production limits dendritic cell migration through extracellular matrix.. Journal of immunology (Baltimore, Md. : 1950), 2004.
  191. Mao JT, Tsu IH, Dubinett SM, Adams B, Sarafian T, Baratelli F, Roth MD, Serio KJ. Modulation of pulmonary leukotriene B4 production by cyclooxygenase-2 inhibitors and lipopolysaccharide.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004.
  192. Krysan K, Dalwadi H, Sharma S, Põld M, Dubinett S. Cyclooxygenase 2-dependent expression of survivin is critical for apoptosis resistance in non-small cell lung cancer.. Cancer research, 2004.
  193. Põld M, Krysan K, Põld A, Dohadwala M, Heuze-Vourc'h N, Mao JT, Riedl KL, Sharma S, Dubinett SM. Cyclooxygenase-2 modulates the insulin-like growth factor axis in non-small-cell lung cancer.. Cancer research, 2004.
  194. Dubinett SM, Elashoff D, Meyerson M. Assessing prognosis in non-small-cell lung cancer: avenues to a more complete picture?. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2004.
  195. Riedl K, Krysan K, Põld M, Dalwadi H, Heuze-Vourc'h N, Dohadwala M, Liu M, Cui X, Figlin R, Mao JT, Strieter R, Sharma S, Dubinett SM. Multifaceted roles of cyclooxygenase-2 in lung cancer.. Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy, 2004.
  196. Zhang L, Keane MP, Zhu LX, Sharma S, Rozengurt E, Strieter RM, Dubinett SM, Huang M. Interleukin-7 and transforming growth factor-beta play counter-regulatory roles in protein kinase C-delta-dependent control of fibroblast collagen synthesis in pulmonary fibrosis.. The Journal of biological chemistry, 2004.
  197. Krysan K, Dohadwala M, Luo J, Lin Y, Zhu L, Heuze-Vourc'h N, Goodglick L, Merchant F, Seligson D, Pold M, Strieter R, Sharma S, Dubinett S. Cyclooxygenase-2-dependent expression of survivin in non-small cell lung cancer.. Chest, 2004.
  198. Yang SC, Hillinger S, Riedl K, Zhang L, Zhu L, Huang M, Atianzar K, Kuo BY, Gardner B, Batra RK, Strieter RM, Dubinett SM, Sharma S. Intratumoral administration of dendritic cells overexpressing CCL21 generates systemic antitumor responses and confers tumor immunity.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2004.
  199. Sandler AB, Dubinett SM. COX-2 inhibition and lung cancer.. Seminars in oncology, 2004.
  200. Põld M, Zhu LX, Sharma S, Burdick MD, Lin Y, Lee PP, Põld A, Luo J, Krysan K, Dohadwala M, Mao JT, Batra RK, Strieter RM, Dubinett SM. Cyclooxygenase-2-dependent expression of angiogenic CXC chemokines ENA-78/CXC Ligand (CXCL) 5 and interleukin-8/CXCL8 in human non-small cell lung cancer.. Cancer research, 2004.
  201. Gardner B, Zhu LX, Roth MD, Tashkin DP, Dubinett SM, Sharma S. Cocaine modulates cytokine and enhances tumor growth through sigma receptors.. Journal of neuroimmunology, 2004.
  202. Hillinger S, Yang SC, Zhu L, Huang M, Duckett R, Atianzar K, Batra RK, Strieter RM, Dubinett SM, Sharma S. EBV-induced molecule 1 ligand chemokine (ELC/CCL19) promotes IFN-gamma-dependent antitumor responses in a lung cancer model.. Journal of immunology (Baltimore, Md. : 1950), 2003.
  203. Mao JT, Roth MD, Serio KJ, Baratelli F, Zhu L, Holmes EC, Strieter RM, Dubinett SM. Celecoxib modulates the capacity for prostaglandin E2 and interleukin-10 production in alveolar macrophages from active smokers.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003.
  204. Krysan K, Merchant FH, Zhu L, Dohadwala M, Luo J, Lin Y, Heuze-Vourc'h N, Põld M, Seligson D, Chia D, Goodglick L, Wang H, Strieter R, Sharma S, Dubinett S. COX-2-dependent stabilization of survivin in non-small cell lung cancer.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003.
  205. Riedl K, Baratelli F, Batra RK, Yang SC, Luo J, Escuadro B, Figlin R, Strieter R, Sharma S, Dubinett S. Overexpression of CCL-21/secondary lymphoid tissue chemokine in human dendritic cells augments chemotactic activities for lymphocytes and antigen presenting cells.. Molecular cancer, 2003.
  206. Sharma S, Batra RK, Yang SC, Hillinger S, Zhu L, Atianzar K, Strieter RM, Riedl K, Huang M, Dubinett SM. Interleukin-7 gene-modified dendritic cells reduce pulmonary tumor burden in spontaneous murine bronchoalveolar cell carcinoma.. Human gene therapy, 2003.
  207. Gardner B, Zhu LX, Sharma S, Tashkin DP, Dubinett SM. Methanandamide increases COX-2 expression and tumor growth in murine lung cancer.. FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2003.
  208. Zhang L, Sharma S, Zhu LX, Kogai T, Hershman JM, Brent GA, Dubinett SM, Huang M. Nonradioactive iodide effectively induces apoptosis in genetically modified lung cancer cells.. Cancer research, 2003.
  209. Sharma S, Yang SC, Hillinger S, Zhu LX, Huang M, Batra RK, Lin JF, Burdick MD, Strieter RM, Dubinett SM. SLC/CCL21-mediated anti-tumor responses require IFNgamma, MIG/CXCL9 and IP-10/CXCL10.. Molecular cancer, 2003.
  210. Zhu LX, Sharma S, Gardner B, Escuadro B, Atianzar K, Tashkin DP, Dubinett SM. IL-10 mediates sigma 1 receptor-dependent suppression of antitumor immunity.. Journal of immunology (Baltimore, Md. : 1950), 2003.
  211. Sharma S, Stolina M, Yang SC, Baratelli F, Lin JF, Atianzar K, Luo J, Zhu L, Lin Y, Huang M, Dohadwala M, Batra RK, Dubinett SM. Tumor cyclooxygenase 2-dependent suppression of dendritic cell function.. Clinical cancer research : an official journal of the American Association for Cancer Research, 2003.
  212. Heuze-Vourc'h N, Zhu L, Krysan K, Batra RK, Sharma S, Dubinett SM. Abnormal interleukin 10Ralpha expression contributes to the maintenance of elevated cyclooxygenase-2 in non-small cell lung cancer cells.. Cancer research, 2003.
  213. Batra RK, Lin Y, Sharma S, Dohadwala M, Luo J, Pold M, Dubinett SM. Non-small cell lung cancer-derived soluble mediators enhance apoptosis in activated T lymphocytes through an I kappa B kinase-dependent mechanism.. Cancer research, 2003.
  214. Dubinett SM, Sharma S, Huang M, Dohadwala M, Pold M, Mao JT. Cyclooxygenase-2 in lung cancer.. Progress in experimental tumor research, 2003.
  215. Tashkin DP, Baldwin GC, Sarafian T, Dubinett S, Roth MD. Respiratory and immunologic consequences of marijuana smoking.. Journal of clinical pharmacology, 2002.
  216. Basak SK, Harui A, Stolina M, Sharma S, Mitani K, Dubinett SM, Roth MD. Increased dendritic cell number and function following continuous in vivo infusion of granulocyte macrophage-colony-stimulating factor and interleukin-4.. Blood, 2002.
  217. Huang M, Sharma S, Zhu LX, Keane MP, Luo J, Zhang L, Burdick MD, Lin YQ, Dohadwala M, Gardner B, Batra RK, Strieter RM, Dubinett SM. IL-7 inhibits fibroblast TGF-beta production and signaling in pulmonary fibrosis.. The Journal of clinical investigation, 2002.
  218. Gardner B, Zu LX, Sharma S, Liu Q, Makriyannis A, Tashkin DP, Dubinett SM. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-beta.. Biochemical and biophysical research communications, 2002.
  219. Miller PW, Sharma S, Stolina M, Butterfield LH, Luo J, Lin Y, Dohadwala M, Batra RK, Wu L, Economou JS, Dubinett SM. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication.. Human gene therapy, 2000.
  220. Arthur JF, Butterfield LH, Roth MD, Bui LA, Kiertscher SM, Lau R, Dubinett S, Glaspy J, McBride WH, Economou JS. A comparison of gene transfer methods in human dendritic cells.. Cancer gene therapy, 1997.
  221. Sharma S, Wang J, Huang M, Paul RW, Lee P, McBride WH, Economou JS, Roth MD, Kiertscher SM, Dubinett SM. Interleukin-7 gene transfer in non-small-cell lung cancer decreases tumor proliferation, modifies cell surface molecule expression, and enhances antitumor reactivity.. Cancer gene therapy, 1996.
  222. Dubinett SM, Huang M, Dhanani S, Economou JS, Wang J, Lee P, Sharma S, Dougherty GJ, McBride WH. Down-regulation of murine fibrosarcoma transforming growth factor-beta 1 expression by interleukin 7.. Journal of the National Cancer Institute, 1995.
  223. Dubinett SM, Kradin RL. Cytokine immunotherapy of non-small cell lung cancer.. Regional immunology, 1993.
  224. Dubinett SM, Patrone L, Huang M, Markowitz J, McBride WH, Economou JS, Tobias J, Kelley D, Yan D, Seelig M. Interleukin-2-responsive wound-infiltrating lymphocytes in surgical adjuvant cancer immunotherapy.. Immunological investigations, 1993.
  225. McDonagh J, Fossel ET, Kradin RL, Dubinett SM, Laposata M, Hallaq YA. Effects of tumor necrosis factor-alpha on peroxidation of plasma lipoprotein lipids in experimental animals and patients.. Blood, 1992.
  226. McBride WH, Thacker JD, Comora S, Economou JS, Kelley D, Hogge D, Dubinett SM, Dougherty GJ. Genetic modification of a murine fibrosarcoma to produce interleukin 7 stimulates host cell infiltration and tumor immunity.. Cancer research, 1992.
  227. Dubinett SM, Callahan RJ, Xia WJ, Ahmad M, Strauss HW, Kradin RL. Cytokine administration alters the distribution of activated lymphocytes to the lung.. Pathobiology : journal of immunopathology, molecular and cellular biology, 1991.
  228. Dubinett SM, Kurnick JT, Kradin RL. Adoptive immunotherapy of murine pulmonary metastases with interleukin 2 and interferon-gamma.. American journal of respiratory cell and molecular biology, 1989.
  229. Gallagher WJ, Dubinett SM, Hoover HC, Kradin RL. Efficacy of adjuvant interleukin-2 after excision of BALB/c fibrosarcomas.. Surgery, 1989.
  230. Kradin RL, Kurnick JT, Lazarus DS, Preffer FI, Dubinett SM, Pinto CE, Gifford J, Davidson E, Grove B, Callahan RJ. Tumour-infiltrating lymphocytes and interleukin-2 in treatment of advanced cancer.. Lancet (London, England), 1989.
  231. Kradin RL, Kurnick JT, Preffer FI, Dubinett SM, Dickersin GR, Pinto C. Adoptive immunotherapy with IL-2 results in the loss of delayed-type hypersensitivity responses and the development of immediate hypersensitivity to recall antigens.. Clinical immunology and immunopathology, 1989.
  232. Kradin R, Dubinett S, Mullin J, Boyle L, Strauss HW, Bourgoin PM, Preffer FI, Kurnick J. Treatment of patients with advanced cancer using tumor-infiltrating lymphocytes and interleukin 2.. Transplantation proceedings, 1988.
  233. Kradin RL, Boyle LA, Preffer FI, Callahan RJ, Barlai-Kovach M, Strauss HW, Dubinett S, Kurnick JT. Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer.. Cancer immunology, immunotherapy : CII, 1987.